NEW YORK, April 16 (Reuters) - Vertex Pharmaceuticals Inc. reported a wider first-quarter loss on Thursday due to high drug development costs and acquisition related and restructuring expenses.
NEW YORK, April 16 (Reuters) - Vertex Pharmaceuticals Inc. reported a wider first-quarter loss on Thursday due to high drug development costs and acquisition related and restructuring expenses.